Distinct proliferative and fibrotic phenotypes exhibit divergent risks and treatment responses. Quantitative cDDD assessment enables objective evaluation of therapeutic intensity and outcome prediction, supporting a stage-tailored, precision approach to IgG4-RD management.
Tsai et al. (Mon,) studied this question.